Market Overview

UPDATE: JP Morgan Raises PT to $29 on Pfizer Following PD-991 Phase II Data

Share:
Related PFE
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
Boeing, Pfizer And Others Band Together To Ask Congress For More Taxes
Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug (Investor's Business Daily)

JP Morgan reiterated Pfizer (NYSE: PFE) at Overweight and increased its price target from $28 to $29.

JP Morgan commented, "Following last week's phase II data for PD-991 in breast cancer and further feedback from physicians, we believe the product represents the most promising of Pfizer's next-generation pipeline assets, and we are incorporating it into our model. We see PD-991 as a multi-billion product opportunity, addressing a large segment of the breast cancer market (first-line advanced/metastatic HER2-/ER+) with few treatment options. More broadly, we believe PFE shares remain positioned to outperform as the company continues with its business unit divestiture process, returns significant capital to shareholders, and enters an attractive new product launch cycle."

Pfizer closed at $25.51 on Wednesday.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight
Nov 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!